Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors.

EGFR vIII:0.12 nM (EC50), EGFR (WT):0.96 nM (EC50), EGFR (1-501):0.66 nM (EC50), EGFR phosphorylation:1.2 nM

Losatuxizumab (ABT-806) binds EGFR with EC50 values of 0.96 nM for EGFR wild type, 0.09 nM for EGFR(C271A,C283A), 0.12 nM for EGFR(vIII), and 0.66 nM for EGFR(1-501).[1]
Losatuxizumab inhibited EGF-induced EGFR phosphorylation with an IC50 of 1.2 nM in the NR6 huEGFR(C271A,C283A) cell line.[2]

Losatuxizumab exhibits antitumor activity against multiple wild-type EGFR-expressing squamous cell carcinoma xenograft models. [1]
Losatuxizumab (40 mg/kg, intraperitoneal) significantly delayed the growth of U87MGde2-7 tumors in mice. [1]
Losatuxizumab (10 and 40 mg/kg, intraperitoneal) prolonged survival in a patient-derived xenograft glioblastoma (PDX GBM) model (SN0207 tumors) while decreasing pEGFR levels in tumor tissue. [1]

Human

Monoclonal

Unconjugated